Quercetin synergistically reactivates human immunodeficiency virus type 1 latency by activating nuclear factor-κB

XINYI YANG, XIAOLI ZHU, HAIYAN JI, JUNXIAO DENG, PANPAN LU, ZHENGTAO JIANG, XIAN LI, YIBO WANG, CHUQIAO WANG, JINGYA ZHAO, YANAN WANG, YANGCHENG ZHONG, HE YANG and HUANZHANG ZHU

State Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai 200433, P.R. China

Received March 31, 2016; Accepted March 16, 2017

DOI: 10.3892/mmr.2017.8188

Abstract. Highly active antiretroviral therapy (HAART) is very effective in suppressing human immunodeficiency virus type 1 (HIV-1) replication. However, the treatment is required to be administered for the remainder of an individual’s lifetime due to latent HIV-1 reservoirs. The ‘shock-and-kill’ strategy, which involves using agents to reactivate latent HIV-1 and subsequently killing latently infected cells in the presence of HAART, was recently proposed. Unfortunately, no agents have currently demonstrated an ability to reactivate latent HIV-1 in vivo in the absence of toxicity. Therefore, the identification of novel latency activators is required. In order to identify a potential novel agent, the present study investigated the effect of quercetin on latent HIV-1 reactivation using an established model of HIV-1 latency. As a marker for reactivation of HIV-1 in C11 Jurkat cells, the expression of green fluorescent protein, controlled by HIV-1 long terminal repeat, was observed by fluorescence microscopy. The results of the present study demonstrated that quercetin effectively reactivated latent HIV-1 gene expression alone, and led to synergistic reactivation when combined with prostratin or valproic acid. In addition, the present study provides evidence that quercetin may reactivate HIV-1 expression by inducing nuclear factor-κB nuclear translocation, and that the toxicity of quercetin is lower when compared with various additional activators of HIV-1. Combined, the results of the present study indicate that quercetin may be an effective agent to disrupt HIV-1 latency and may be useful in future eradication strategies.

Introduction

Although highly active antiretroviral therapy (HAART) has been proven to suppress human immunodeficiency virus type 1 (HIV-1) replication to undetectable levels, interrupting HAART allows the virus to rapidly increase in numbers when compared with pretreatment levels (1,2). Previous studies have demonstrated that latently infected cells are major obstacles to treatment success, and these cells are not eliminated by HAART (3-5). In addition, previous studies have demonstrated that the estimated size of this latent reservoir is $10^5$-$10^6$ cells/patient (6,7). It has been proposed that, for the complete eradication of HIV-1, patients would be required to receive HAART for >70 years (6,7). However, this therapy is expensive and associated with toxic effects. For these reasons, elimination of the latent reservoir of HIV-1 is an important aim.

Although the mechanisms that establish and maintain HIV-1 latency are not well defined, specific factors may contribute to HIV-1 latency, including activator protein-1 (AP-1), nuclear factor of activated T-cells (NFAT), nuclear factor-κB (NF-κB) and specificity protein 1 (SPI) (8). In addition, in latently infected cells, various studies have demonstrated that the genomes of HIV-1 are present within genes that are actively transcribed (9,10). Therefore, transcriptional interference of the host gene may contribute to viral latency (9-11). In addition, histone deacetylation, DNA methylation, histone methylation and additional specific epigenetic modifications may silence HIV-1 transcription and expression (12).

To eradicate latent HIV-1 infection, the ‘shock and kill’ strategy was proposed, which involves reactivation of latent HIV-1 expression by various agents followed by the killing of infectious cells by additional methods (13). Numerous potential agents that may reactivate latent HIV-1 infection have been identified, and the agents that have been investigated with regards to eradication of latent HIV-1 are divided into the following seven groups: Histone deacetylase inhibitors, including suberoylanilide hydroxamic acid/vorinostat (14), valproic acid (VPA) (15), sueroyl bis-hydroxamic (16), panobinostat, givinostat, belinostat (17) and M344 (18); cytokines and chemokines, including tumor necrosis factor α (TNF-α) (19) and NF-κB (20); DNA methyltransferase inhibitors, which...
primarily include decitabine (2′-deoxy-5-azacytidine) and its analogs (21); histone methyltransferase inhibitors, such as BIX01294 (22); protein kinase C activators such as prostratin (23); positive transcription elongation factor b activators, which include hexamethyle bisacetamide (24); and particular unclassified agents, such as disulfiram (25). However, due to limitations of effectiveness and toxicity, the agents may not be suitable when administered alone. Therefore, an increasing number of studies have focused on identifying a cocktail of agents that reactivate latent HIV-1 infections. Ideally, agents or agent cocktails used to eradicate latent reservoirs should be highly efficient at reactivating latent HIV-1, not induce global T-cell activation, and must exhibit acceptable pharmacological and toxicological properties. To the best of the author's knowledge, no agents that effectively disrupt HIV-1 latency and exhibit low toxicities have been identified thus far. Therefore, the identification of novel agents, and particular agent combinations is required.

Quercetin is a flavonol that is present in various plant-based foods, including onions, apples, citrus fruits, berries, red grapes, red wine, broccoli, tea, flowers and bark roots (26). It has been used as a treatment for various conditions, including allergies, asthma, bacterial infections, arthritis, gout, eye disorders, hypertension and neurodegenerative disorders (26).

Previous studies have indicated that quercetin may potentially inhibit the HIV-1 integrase and reverse transcriptase enzymes (27,28); however, limited information regarding the role of quercetin in combating latent HIV-1 infections is known. Therefore, the present study aimed to investigate the ability of quercetin to reactivate latent HIV-1. To achieve this, the ability of quercetin to induce HIV-1 expression in latently infected cells, as well as the potential underlying molecular mechanisms, were investigated. In addition, the effect of quercetin in combination with additional activators was investigated. The results demonstrated that quercetin reactivated latent HIV-1 in an in vitro model of HIV-1 latency potentially via the NF-κB signaling pathway, and synergistically reactivated HIV-1 latency when combined with VPA or prostratin.

The results indicated that either of these combinations may be useful as a potential anti-latency therapy.

Materials and methods

Cell culture and chemical treatment. C11 cells, a type of latently infected Jurkat cell, were generated in our laboratory (Shanghai, China) and have been employed in previous studies (29-31). Briefly, cells were transfected with a construct (donated by the National Institutes of Health, Bethesda, MD, USA) that encodes green fluorescent protein (GFP) as a marker for Tat-driven HIV-1 long terminal repeat (LTR) expression; lentiviral transfection was performed as previously described (32). The C11 cells were cultured in RPMI-1640 medium (Corning Incorporated, Corning, NY, USA) supplemented with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), 100 U/ml penicillin and 100 µg/ml streptomycin (Invitrogen; Thermo Fisher Scientific, Inc.) at 37°C and 5% CO2. The HEK 293T human endothelial kidney cell line was purchased from the American Type Culture Collection (Manassas, VA, USA), and cells were cultured in Dulbecco’s modified Eagle's medium (Gibco; Thermo Fisher Scientific, Inc.) with 10% FBS, 100 U/ml penicillin and 100 µg/ml of streptomycin at 37°C and 5% CO2. Quercetin was purchased from Sigma-Aldrich; Merck KGaA (Darmstadt, Germany) and VPA was purchased from InvivoGen (San Diego, CA, USA). Prostratin was purchased from LC Laboratories (Woburn, MA, USA). Recombinant human TNF-α was purchased from EMD Millipore (Billerica, MA, USA). Quercetin (100 mM), TNF-α (1 mg/ml), VPA (100 mM) and prostratin (10 mM) were dissolved in anhydrous dimethylsulfoxide and stored at -20°C.

Visualization of GFP. As GFP was used as the marker of HIV-1 expression, the expression of GFP was observed by fluorescence microscopy to confirm reactivation. C11 cells (3x10⁴) were treated at 37°C and 5% CO2 with quercetin (20 µM) or mock (0 µM). C11 cells (6x10⁴) were subsequently viewed using a Nikon fluorescence microscope (Nikon Corporation, Tokyo, Japan). All microscope samples were imaged across 10 random fields using a Nikon E2 digital camera (Nikon Corporation), and images were analyzed using EIS Element F 3.0 (Nikon Corporation).

Flow cytometry. C11 cells (6x10⁴) were washed with phosphate-buffered saline (PBS) and incubated with the following treatments: Quercetin (20 µM) or mock treatment for 72 h; quercetin (20 µM) or mock treatment for 0, 24, 48, 72 and 96 h; quercetin (5, 10, 20 and 40 µM) or mock treatment for 72 h; quercetin (20 µM), mock (0 µM) treatment, VPA (2 mM), prostratin (200 nM), quercetin (20 µM) + VPA (2 mM) and quercetin (20 µM) + prostratin (200 nM) for 72 h. Cells were cultured in RPMI-I640 medium supplemented with 10% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin, at 37°C and 5% CO2. Cells were treated with 1 ml PBS for 5 min and resuspended in 300 µl PBS. GFP expression was measured using a FACScan flow cytometer (BD Biosciences, Franklin lakes, NJ, USA), and FACS data were analyzed with FlowJo software version 10.0 (FlowJo LLC, Inc., Ashland, OR, USA). GFP-associated fluorescence was differentiated from background fluorescence by the gating of live cells (10,000 events in total) and by two-parameter analysis. For all analyses, three independent experiments were performed, and samples were analyzed in triplicate.

Cytotoxicity assay. Cell proliferation and viability were measured using a Cell Counting Kit-8 assay (CCK-8; Dojindo Molecular Technologies, Inc., Rockville, MD, USA) (30,33). C11 cells were seeded in 96-well plates (~4x10⁴ cells per well) before they were treated with 0, 5, 10, 20, 40, 80 and 160 µM quercetin for 48 h at 37°C and 5% CO2. This was followed by the addition of 10 µl CCK-8 solution to each well of the plate. Following incubation for 4 h at 37°C, the absorbance was read at 450 nm using a microplate reader. For each sample, the half maximal inhibitory concentration (IC₅₀) was measured in triplicate and at least three independent assays were performed.

Transient transfection and luciferase assays. HEK 293T cells were plated at 1x10⁵ cells/well in 24-well plates at 24 h prior to transfection, and were transfected using Lipofectamine® 2000 according to the manufacturer’s protocol (Invitrogen; Thermo Fisher Scientific, Inc.). The HIV-1 LTR-luc (1.0 µg;
Quercetin reactivates latent HIV-1 replication. In order to assess the induction of HIV-1 expression in latently infected cells by quercetin, C11 cells that were established in our lab were employed. These cells are Jurkat T cells latently infected with a single provirus integrated into intron 3 of the RNA binding protein with serine rich domain 1 gene, combined with a GFP gene and under the control of the HIV-1 LTR, and was used as a marker of HIV-1 LTR expression (31). The structure of quercetin is presented in Fig. 1A. Quercetin (20 µM) was used to treat C11 cells for 72 h, and fluorescence microscopy analysis indicated ~10% C11 cells were positive for HIV-1 LTR expression (Fig. 1B). Subsequently, as GFP was used as a marker of HIV-1 expression, flow cytometry was performed to detect the percentage of GFP-positive cells (Fig. 1C). The results indicated that the HIV-1 transcriptional activity increased to 14.50% following treatment with quercetin (20 µM) for 72 h, compared with 3.12% in mock-treated cells. To analyze the kinetics of HIV-1 LTR expression induced by quercetin, a kinetics experiment was performed where quercetin (20 µM) or mock-treated C11 cells were cultured for 1-4 days. At each time point, flow cytometry analysis was performed to determine the proportion of GFP-expressing cells. Following treatment with quercetin, the percentage of GFP-expressing cells increased for the first 3 days and then plateaued at day 4, whereas no increase in GFP-positive cells was observed in the mock-treated group over the same time period (Fig. 2A). These results indicated that quercetin may affect HIV-1 expression in a time-dependent manner. To determine the effect of increasing concentrations of quercetin on HIV-1 production, cells were treated with 5, 10, 20 and 40 µM quercetin for 72 h. The percentage of GFP-expressing cells was increased by between 3- and 6-fold compared with the mock-treated cells (Fig. 2B). The results demonstrated that quercetin induced HIV-1 LTR reactivation in a concentration-dependent manner.

Quercetin synergistically reactivates latent HIV-1 production. As quercetin is effective and less toxic than prostratin (37), the present study assessed whether quercetin synergistically reactivates HIV-1 in C11 cells when combined with VPA or prostratin. C11 cells were treated with quercetin alone (20 µM), VPA alone (2 mM), prostratin alone (200 nM), quercetin (20 µM) + VPA (2 mM), quercetin (20 µM) + prostratin (200 nM) or received mock treatment for 72 h. The percentage of GFP-expressing cells was increased by between 3- and 6-fold compared with the mock-treated cells (Fig. 2B). The results demonstrated that quercetin induced HIV-1 LTR reactivation in a concentration-dependent manner.

Quercetin synergistically reactivates latent HIV-1 production. As quercetin is effective and less toxic than prostratin (37), the present study assessed whether quercetin synergistically reactivates HIV-1 in C11 cells when combined with VPA or prostratin. C11 cells were treated with quercetin alone (20 µM), VPA alone (2 mM), prostratin alone (200 nM), quercetin (20 µM) + VPA (2 mM), quercetin (20 µM) + prostratin (200 nM) or received mock treatment for 72 h. The percentage of GFP-expressing cells was increased by between 3- and 6-fold compared with the mock-treated cells (Fig. 2B). The results demonstrated that quercetin induced HIV-1 LTR reactivation in a concentration-dependent manner.

Quercetin synergistically reactivates latent HIV-1 production. As quercetin is effective and less toxic than prostratin (37), the present study assessed whether quercetin synergistically reactivates HIV-1 in C11 cells when combined with VPA or prostratin. C11 cells were treated with quercetin alone (20 µM), VPA alone (2 mM), prostratin alone (200 nM), quercetin (20 µM) + VPA (2 mM), quercetin (20 µM) + prostratin (200 nM) or received mock treatment for 72 h. The percentage of GFP-expressing cells was increased by between 3- and 6-fold compared with the mock-treated cells (Fig. 2B). The results demonstrated that quercetin induced HIV-1 LTR reactivation in a concentration-dependent manner.

Quercetin synergistically reactivates latent HIV-1 production. As quercetin is effective and less toxic than prostratin (37), the present study assessed whether quercetin synergistically reactivates HIV-1 in C11 cells when combined with VPA or prostratin. C11 cells were treated with quercetin alone (20 µM), VPA alone (2 mM), prostratin alone (200 nM), quercetin (20 µM) + VPA (2 mM), quercetin (20 µM) + prostratin (200 nM) or received mock treatment for 72 h. The percentage of GFP-expressing cells was increased by between 3- and 6-fold compared with the mock-treated cells (Fig. 2B). The results demonstrated that quercetin induced HIV-1 LTR reactivation in a concentration-dependent manner.
resulted in synergistic reactivation of latent HIV-1 production in C11 cells.

**Quercetin exhibits no apparent toxicity in vitro.** The toxicity of quercetin was investigated to determine whether it may be ideal therapeutic agent for reactivation of latent HIV-1. C11 cells were treated with 0.5, 10, 20, 40, 80 and 160 µM quercetin for 72 h, and cell viability was subsequently analyzed using CCK-8 assay. At its active concentration (20 µM), quercetin exhibited no significant toxicity in C11 cells (Fig. 4).

**Quercetin activates the HIV-1 LTR through induction of NF-κB.** The present study subsequently investigated the signaling pathway through which quercetin may mediate activation of the HIV-1 LTR. Binding sites for a number of inducible transcription factors, including NF-κB, AP-1 and SP1, are located within the HIV-1 LTR (39). To determine the role of particular transcription factors in the activation of the HIV LTR by quercetin, the present study employed HEK 293T cells that were transfected with luciferase reporter plasmids containing the wild-type HIV-1 LTR, LTR lacking two κB enhancers, LTR lacking AP-1 enhancers or LTR lacking SP1 enhancers. TNF-α was selected as a positive control. Compared with mock controls, TNF-α induced ~3.65-fold upregulation of the HIV-1-LTR-luc reporter, ~2.98-fold upregulation of the HIV-1-LTR (ΔAP-1)-luc and
~3.11-fold upregulation of HIV-1-LTR (ΔSPI) -luc reporter; however, TNF-α failed to activate the HIV-1-LTR (ΔκB)-luc reporter (Fig. 5A). Similarly, quercetin induced ~1.56-fold upregulation of the HIV-1-LTR luc reporter, ~1.53-fold upregulation of the HIV-1-LTR (ΔAP-1)-luc and HIV-1-LTR (ΔSPI)-luc reporters, whereas it failed to activate the HIV-1-LTR (ΔκB)-luc reporter. These results indicated that NF-κB transcription factors may serve an important role in quercetin-mediated activation of latent HIV-1 LTR expression. In order to further confirm the involvement of NF-κB signaling pathway in quercetin-mediated activation of latent HIV-1 LTR expression, an EMSA was performed to assess whether quercetin treatment was a sufficient stimulus for NF-κB nuclear translocation and DNA binding. Nuclear extracts from C11 cells treated with quercetin or TNF-α were incubated with biotin-labeled NF-κB enhancer DNA probes. *P<0.05 and ***P<0.001 vs. mock treated cells; **P<0.01 vs. HIV1-LTR (ΔκB) luc-infected cells. HIV-1, human immunodeficiency virus type 1; NF-κB, nuclear factor-κB; LTR, long terminal repeat; luc, luciferase; AP-1, activator protein-1; SPI, specificity protein 1; TNF-α, tumor necrosis factor-α.

Discussion

Although recent studies investigating the clinical consequences of latent HIV-1 infection have made progress, the persistence of the latent reservoir of integrated HIV-1 proviruses in resting CD4+ T cells is a major obstacle for viral eradication (40). Therefore the development of an effective treatment for HIV-1 infection remains a challenge (41). Reactivation of the latent provirus in patients receiving HAART is a promising strategy for the depletion of the latent viral reservoir (42). In order to achieve this aim, Katlama et al (43) proposed a three-tiered strategy to reactivate the latent cells and eliminate viral reservoirs. The first and most important step is to reactivate the expression of the latent HIV-1 provirus. Therefore, various studies have focused on agents that target different mechanisms of HIV-1 latency, including VPA, TNF-α and prostratin (44).
However, the toxicity and ineffectiveness of these agents in clinical trials and the necessity for prolonged treatment limit the applications of these agents (45). It is thought that treatment with a combination of agents may be less toxic and more effective (46). Therefore, the identification of improved treatment combinations that demonstrate increased specificity is required.

Quercetin, a flavonol that is used in the treatment of allergies, asthma, bacterial infections, arthritis, gout, eye disorders, hypertension and neurodegenerative disorders (27). Quercetin has demonstrated the ability to treat HIV-1 as a drug in HAART (47); however, there is limited information regarding the effect of quercetin on HIV-1 latency. Therefore, the present study used a simple in vitro model of latent HIV-1 infection in order to investigate whether quercetin reactivates latently infected C11 cells. A plasmid vector encoding GFP under the control of the HIV-1 LTR was transfected into C11 cells, and used as a marker of HIV-1 expression. The expression of the HIV-1 LTR was detected by fluorescence microscopy and flow cytometry (30). The results demonstrated that quercetin effectively reactivated HIV-1 latency and exhibited low toxicity in C11 cells at concentrations ≤20 µM. In addition, the results demonstrated that latent HIV-1 replication was activated by quercetin in a time- and concentration-dependent manner.

Compared with prostratin and additional activators, the effect of quercetin alone on HIV-1 reactivation is weak; however, quercetin is less toxic to cells (37,46). Therefore, the current study investigated whether synergistic activation of HIV-1 occurred when quercetin was combined with VPA or prostratin in C11 cells. VPA and prostratin were selected as they demonstrate a potent effect on the reactivation of infection in latently infected cell lines and ex vivo primary cells (48,49). The results of the present study demonstrated that co-treatment with quercetin plus VPA or quercetin plus prostratin induced HIV-1 expression in a higher percentage of C11 cells when compared with each activator alone. These results indicated that quercetin combined with VPA or prostratin may lead to synergistic reactivation of HIV-1 production at a lower concentration in C11 cells, therefore, lower concentrations of these agents may be used to reactivate latent HIV-1 cells. These results are consistent with previous studies demonstrating that co-treatment with an NK-κB inducer and histone deacetylase inhibitor synergistically increased the proportion of J-Lat cells displaying GFP fluorescence when compared with treatment with each compound in isolation (36,50), and one study reported that prostratin synergizes with other activators to promote activation of latent HIV via NF-κB (51).

Viral and cellular transcription factors with binding sites in the HIV-1 LTR serve an important role in the expression of latent HIV-1. The HIV-1 LTR contains several DNA-binding sites for various cellular transcription factors, including NFAT, AP-1, SP1, NF-κB, lymphoid enhancer binding factor 1, C/EBP transcription factor 2, ETS proto-oncogene 1 and upstream stimulatory factor (52,53). Of these, NF-κB serves an important role in the reactivation pathway of latent HIV-1. A previous study reported that quercetin inhibited inflammation associated with NF-κB in specific cell lines (54). Therefore, the present study investigated whether the NF-κB signaling pathway may be involved in the quercetin-mediated activation of the latent HIV-1 LTR in C11 cells. The results indicated that quercetin effectively reactivated the wild-type HIV-1 LTR-luc, the HIV-LTR (ΔAP-1)-luc and the HIV-LTR (ΔSP1)-luc reporters, whereas, it failed to activate the LTR reporter lacking the κB enhancers. In addition, the results indicated that nuclear translocation of NF-κB was induced by quercetin in a concentration-dependent manner as determined by EMSA analysis. Together, the results of the current study indicate that quercetin may activate HIV-1 gene expression via the NF-κB signaling pathway.

In conclusion, the HIV-1 viral reservoir is a major obstacle to the eradication of the provirus in patients receiving HAART. A current therapeutic strategy, termed ‘shock-and-kill’, has been proposed as a promising solution to eradicate HIV-1 reservoirs in the presence of HAART. For this therapy to be successful, the primary and most important aim is to identify a method of inducing latent HIV-1 gene expression. Due to the limitations of ineffectiveness and toxicity, the agents that have previously been investigated have failed in the clinic (44). Therefore, the identification of agents that exhibit lower toxicity is required. The current study demonstrated that quercetin is a potent activator of HIV-1 latency that lacks obvious cytotoxicity and may function via the NF-κB signaling pathway. Notably, the results indicated that quercetin synergizes with VPA or prostratin in the induction of HIV-1 transcription. In addition, a previous study demonstrated that the majority of agents that have been identified, and that do not cause global T cell activation, are ineffective in the clinic (44). Therefore, it is important to identify agents that may reactivate latent HIV-1 without global T cell activation. The results of the current study suggest that quercetin may meet these criteria. However, this study employed an in vitro model of HIV-1 latency, therefore further investigation into the effects of quercetin in a wider population of latent HIV-1 infected cells from HAART-treated patients will be required to explore this agent as a potential drug candidate. In addition, further investigation as to whether quercetin may lead to global T cell activation should be performed.

Acknowledgements

The present study was supported by the Shanghai Scientific Research Plan Project (grant no. 14401902000) and the National Natural Science Foundation of China (grant no. 31501032).

References


52. Mexican MOLECULAR MEDICINE REPORTS  17:  2501-2508,  2018


Chan JK, Bhattacharyya D, Lassen KG, Ruelas D and Greene WC: Calcium/calcineurin synergizes with prostratin to promote NF-κB dependent activation of latent HIV. PLoS One 8: e77749, 2013.